Kala Bio Inc.
KALA - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$12.4K
Close$
$0.93
454.7% upside
Current Fair Value
454.7% upsideUndervalued by 454.7% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $12,399.00 |
|---|---|
| Enterprise Value | $-216,601.00 |
| Earnings per Share | $-165.5 |
| Beta | -2.41 |
| Outstanding Shares | 74,159 |
Return
| Return on Equity | -93.53% |
|---|---|
| Return on Assets | -79.94% |
| Return on Invested Capital | -273.71% |
Valuation & Multiples
| P/E Ratio | 0 |
|---|---|
| PEG | 0 |
| Price to Sales | - |
| Price to Book Ratio | 0.0 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.12 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 19, 2026
EPS Estimate
$-6.00
Consensus analyst estimateRevenue Estimate
$25.00 M
Consensus analyst estimateNext Earnings Call
Expected Date
November 10, 2026
EPS Estimate
$-6.00
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 945.54%▲ 924.69% |
|---|---|
| Total Invested | $1.21M▲ 312.71% |
| Investors Holding | 14▼ 12.00% |
About Kala Pharmaceuticals Inc
6 employees
CEO: Mark Iwicki
Kala Bio, Inc. operates as a biopharmaceutical enterprise focused on developing and bringing to market innovative treatments. The company employs its unique, proprietary nanoparticle technology, designed to effectively penetrate mucus ba...